Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 21986300)

1.

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Graham DY, Jewell NP, Chan FK.

Am J Med Sci. 2011 Nov;342(5):356-64. doi: 10.1097/MAJ.0b013e3182113658.

2.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
3.

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.

Curr Med Res Opin. 2004 Oct;20(10):1539-48.

PMID:
15462687
4.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
6.
7.

Rofecoxib and clinically significant gastrointestinal events.

Bombardier C, Laine L, Day R, Hawkey CJ, Hochberg MC, Schnitzer TJ.

Am J Med Sci. 2011 Nov;342(5):438-9. doi: 10.1097/MAJ.0b013e31822f3ff4. No abstract available.

PMID:
22030845
9.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group.

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

10.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
11.

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.

Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A.

Gastroenterology. 2002 Oct;123(4):1006-12.

PMID:
12360461
12.

Rofecoxib for the treatment of rheumatoid arthritis.

Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2002;(3):CD003685. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD003685.

PMID:
12137705
13.

Rofecoxib for the treatment of rheumatoid arthritis.

Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2002;(2):CD003685. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD003685.

PMID:
12076502
14.
15.

Rofecoxib for osteoarthritis.

Garner SE, Fidan DD, Frankish R, Maxwell L.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005115. Review.

PMID:
15654705
16.

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.

Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. Erratum in: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):669.

PMID:
15937867
17.
18.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
19.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
20.

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE.

Clin Ther. 2001 Jul;23(7):1061-79. Review.

PMID:
11519771
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk